N-Acetyl Semax (25mg)

N-Acetyl Semax Peptide

N-Acetyl Semax is posited to be an acetylated form of the Semax peptide. The peptide consists of a 4 amino acid fragment (Met-Glu-His-Phe) from the chain of melanocortin hormones. These include the adrenocorticotropic hormone (ACTH) and a Pro-Gly-Pro fragment. The integration of Pro-Gly-Pro (PGP) into N-Acetyl Semax may potentially enhance the permeability of the peptide through the blood-brain barrier (BBB). This enhancement might occur by increasing the peptide’s lipophilicity, thereby potentially improving passive diffusion or uptake via lipid raft-mediated endocytosis.

This process may hypothetically allow the peptide to bypass the BBB’s tight junctions, which researchers claim are usually highly restrictive. Adding PGP at the C-terminus might also modify the peptide’s interactions with specific BBB transporters or receptors, possibly facilitating receptor-mediated transcytosis. Receptor-mediated transcytosis is a process where substances are transported across cells via specific receptors, and alterations at the C-terminus might influence this pathway.

Researchers have noted that the acetylation of the peptide into N-Acetyl Semax appears to reduce the affinity of other ions, such as Cu++, to its N-terminus.^[1] Acetylation may contribute to an increase in the peptide’s resistance to enzymatic degradation, potentially leading to an extended half-life observed in experimental models. Increased resistance to degradation might mean that the peptide potentially remains active for a longer period, which may enhance its stability./p>

Specifications

Molecular Formula: C₃₇H₅₁N₉O₁₀S

Molecular Weight: 858.97 g/mol

Sequence: Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2

N-Acetyl Semax Research

N-Acetyl Semax and Nootropic Potential

N-Acetyl Semax may carry similar or potentially greater nootropic potential than its unmodified counterpart, Semax. Current research is primarily based on investigations into Semax itself. According to available data, Semax may hold significant potential for enhancing memory and attention,[2] with experimental models exposed to the compound demonstrating 71% aptitude on memory recall tasks, compared to an average of 41% observed in the control group. A separate trial also reported that Semax may substantially increase activation across various brain regions, as observed through functional magnetic resonance imaging (MRI). Lebedeva et al. concluded that “a greater volume of the default mode network rostral (medial frontal cortex) subcomponent was detected in the Semax group in comparison with controls. Resting state fMRI confirmed [potential] Semax effects on the neuronal network of the brain.”[3]

N-Acetyl Semax and Neurotrophic Factors

Existing Semax research may serve as a foundation for future N-Acetyl Semax investigations into its potential effects on neurotrophic factors. The proposed neuroprotective action of Semax may stem from its capacity to activate and elevate levels of neurotrophic factors in the brain, including Brain-Derived Neurotrophic Factor (BDNF) — a protein considered essential for neuronal growth, maintenance, and survival, and recognized for its role in learning, memory, and higher cognitive function.

Researchers suggest the peptide may contribute to a notable 1.4-fold increase in hippocampal BDNF protein levels, with control experiments in the cerebellum showing no corresponding change — implying a potentially region-specific effect attributable to Semax. Subsequent analyses examined whether this increase in BDNF may activate the BDNF/trkB signaling pathway, with trkB representing the primary BDNF receptor. Tyrosine phosphorylation of trkB receptors — a recognized marker of trkB activation — was observed to increase by 1.5-fold, suggesting that Semax may enhance BDNF signaling through trkB activation.

Furthermore, Semax exposure appeared to result in a threefold increase in BDNF exon III mRNA levels, while trkB mRNA levels were observed to double within the first 24 hours following exposure — potentially indicating that Semax may influence the transcriptional regulation of both BDNF and its receptor trkB.[4] Clinical research further suggests that Semax may increase BDNF expression and may also carry potential applications in ischemic stroke research models. One study involving 110 ischemic stroke models indicated that standard interventions delivered alongside the peptide may have produced a significant increase in BDNF levels,[5] with this increase reported to correlate with improved post-stroke recovery. Gusev et al. noted that “there was a positive correlation between BDNF plasma levels and Barthel score, as well as a correlation between early rehabilitation and motor performance improvement.” A further trial suggested that Semax may exert neuroprotective effects on the optic nerve in glaucoma models.[6]

N-Acetyl Semax and the Digestive System

Similar to Semax, N-Acetyl Semax may carry potential actions relevant to digestive tissue. Researchers have suggested that Semax may help attenuate ulcer development, with a 2002 study published in the Bulletin of Experimental Biology and Medicine indicating that N-Acetyl Semax may be approximately three times more effective than a control compound in potentially accelerating recovery following gastric ulceration.[7] Researchers reported that 14 days of Semax exposure appeared to result in ulcer healing in approximately 90% of receiving research models — a substantial outcome when compared to just over 30% in the experiment’s control group.

N-Acetyl Semax and Enkephalin Signaling

While research specifically examining N-Acetyl Semax remains limited, trials involving Semax suggest the peptide may potentially interact with enkephalin signaling within neural tissues. Investigations indicate that certain enzymes responsible for enkephalin degradation may be inhibited by Semax, potentially producing distinct outcomes observed under laboratory conditions.[8] Enkephalins are endogenously produced neurotransmitters in the brain, considered to play critical roles in processes including nociception — the neuronal perception of pain — and various stress responses.

An increase in enkephalin levels is hypothesized to influence the functioning of other neurotransmitter systems given the complex interrelationships within the opioid system, potentially including dopaminergic and serotonergic systems. Such interactions might result in alterations to neurotransmitter release, changes in receptor activity, or modifications to signal transduction pathways — though the precise mechanisms and outcomes remain uncertain and require further investigation.

N-Acetyl Semax and Serotonin and Dopamine Signaling

Research on N-Acetyl Semax remains limited, though available studies suggest that Semax may interact with and potentially enhance serotonergic neurotransmitter systems, possibly helping to restore or stabilize neural pathways and balance excitatory and inhibitory signaling within the brain.[9]

Research further suggests the peptide may play a role in protecting or correcting neural circuits over a period extending beyond the initial exposure window. In a series of murine experiments, Semax exposure was associated with changes in levels of 5-hydroxyindoleacetic acid (5-HIAA) — a key serotonin metabolite — suggesting a possible enhancement of serotonergic activity. Serotonin is widely recognized as a neurotransmitter influencing mood and cognitive function, and researchers observed a progressive increase in 5-HIAA levels following Semax exposure, rising to as high as 180% in some models.[10] When Semax was introduced 20 minutes prior to D-amphetamine exposure, higher 5-HIAA levels were observed relative to Semax administered alone, further suggesting that the peptide may influence serotonin metabolism and potentially affect serotonin-dependent pathways.

Regarding dopamine, researchers propose that Semax does not appear to directly affect dopamine levels or its metabolites. However, it may modulate the dopaminergic system’s responsiveness, potentially amplifying the effects of dopaminergic agonists. Given dopamine’s recognized roles in reward, motivation, and motor control, this modulation may carry meaningful implications for conditions involving dopaminergic dysregulation.[10]

N-Acetyl Semax and Neuroinflammation

While specific N-Acetyl Semax research remains limited, Semax trials have aimed to examine the peptide’s potential effects on proteins involved in inflammation and cell death — including MMP-9, c-Fos, and JNK — as well as neuroprotective and recovery-associated proteins such as CREB. Semax exposure has been suggested to upregulate active CREB in subcortical structures, including areas of hypothetical ischemic damage, while concurrently MMP-9 and c-Fos appeared to downregulate in the adjacent frontoparietal cortex, and active JNK was observed to downregulate in both the subcortex and cortex. This collectively suggests that Semax may contribute to suppression of inflammatory and apoptotic processes, potentially supporting neuroprotective outcomes.

The regulatory mechanisms proposed to underlie these findings include hypothetical modulation of intracellular signaling pathways. pJNK upregulation during ischemia has been linked to pathways associated with neuroinflammation and apoptosis, and the downregulation of pJNK observed with Semax exposure may reflect altered activity within stress-response and neuroprotective pathways. This hypothesized downregulation of JNK kinases across both subcortical and cortical regions may represent part of a compensatory mechanism activated by Semax, potentially reducing the stress-related signaling contributing to ischemic cell death.

MMP-9 — proposed to destabilize the blood-brain barrier and promote edema — was observed at elevated levels under ischemic conditions. Semax did not appear to significantly affect MMP-9 levels in the subcortex, though the peptide appeared to downregulate its expression in the cortex, suggesting the presence of a region-specific regulatory action that may help protect functionally compromised cells adjacent to infarction zones.

The transcription factor c-Fos, involved in post-ischemic inflammation and cell death, was reported to show increased cortical levels under ischemic conditions. Semax is hypothesized to have contributed to a measurable reduction in cortical c-Fos levels — consistent with the peptide’s proposed capacity to attenuate glutamate excitotoxicity and potentially reduce ischemic cell death — though no significant effect on subcortical c-Fos levels was observed.

Active CREB (pCREB), considered to play a critical role in neurogenesis and neuronal survival, was observed to decrease in subcortical structures following ischemia-reperfusion — an effect hypothetically reversed by Semax exposure, highlighting the peptide’s potential to support neuroprotective pathways under ischemic conditions. Notably, no significant changes in pCREB levels were observed in cortical regions, potentially indicating differential regional responses to both ischemia and Semax exposure.[11]

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

References